Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1846-1850

  Nagata, Naoki ^a   Kimura, Masayuki ^b   Hirabayashi, Naoki ^c   Tuburaya, Akira ^d   Murata, Teruo ^e   Kondo, Ken ^f   Fukuda, Yasuhiko ^g   Kobayashi, Michiya ^h   Miyashita, Yumi ⁱ   Nakao, Akimasa ^j   Sakamoto, Junichi ^k  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b ST MARIANNA UNIVERSITY   (Japan)

^c Asa Municipal Hospital

^d KANAGAWA CANCER CENTER   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^g HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^h KOCHI MEDICAL SCHOOL   (Japan)

ⁱ Non Profit Organization ECRIN

^j NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chemotherapy; Cisplatin; Gastric cancer; Paclitaxel; Phase II study

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; UFT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRITIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REPEATED DRUG DOSE; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; STOMACH NEOPLASMS;

EID: 57049095913     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Nakajima T, Ohta K, Okayama: Tabular analysis of CIH (Cancer Institute Hospital) database: Multimodality therapy for gastric cancer. Tokyo: Springer Verlag, 1999; pp. 197-267.
2. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouacil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72:37-41.
3. Glimelius B, Hoffman K, Haflund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5:189-190.
4. Phyhonen S, Kuitunen T, Nyandoto P, et al: Randomized comparison of fluorouracil epidoxorubicin and methotreate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
5. Preusser P, Wilke H, Achterrath W, et al: Phase II study with the combination etoposide, doxorubicin and cisplatin advanced measurable gastric cancer. J Clin Oncol 1989; 7:1310-1317.
6. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wie and HS: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 1986; 4:1053-1057.
7. Shabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr.: Cis-Dichloro diammineplatinum(ll): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63:1459-1473.
8. Vanhoefer U, Rougler P. Wilke H, et al: Final results of randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer. A trial of European Organization for Research and Treatment of Cancer Gastrointestinal Tract Center Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
9. Scheithauer W, Kornek G, Zeh B, et al: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer randomized trial. Second International Conference on Biology. Prevention and Treatment of GI Malignancy, Koln, Germany, 1995; p. 68. (Abstract)
10. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4:269-274.
11. Boku N, Ohtsu A, Shimade Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319-323.
12. Sakata Y, Ohtsu A, Horikoshi N, et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34:1715-1720.
13. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58:191-197.
14. Matsuoka H, Yano K, Saito Y, Tomoda H: Cytotoxicity of paclitaxel in comparison with other anticancer agents against neoplastic cells obtained from clinical gastrointestinal carcinoma tissue. Anticancer Res 1995; 15:2001-2006.
15. Murad AM, Petroianu. A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer. a novel, safe and effective regimen. Am J Clin Oncol 1999; 22:580-586.
16. Kollmannsberger C, Quietzsch D, Haag C, et al: A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83:458-462.
17. Gadgeel SM, Shields AF, Heilbrun LK, et al: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003; 26:37-41.
18. Kornek GV, Raderer M, Schull B et al: Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 2002; 86:1858-1863.
19. Park SR, Oh DY, Kim DW, et al: A multi-center, late phase II clinical trial of genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004; 12:1059-1064.
20. Yamaguchi K, Tada M, Horikoshi N, et al: Phase II study of paclitaxel with 3-hr infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 5:90-95.
21. Yamada Y, Shirao K, Ohtsu A, et al: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12:1133-1137.
22. Lee KW, Im SA, Yun T et al: Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol 2005; 35(12):720-726.
23. Yamaguchi K, Shimamura T, Komatu Y et al: Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer. Gastric Cancer 2006; 9:36-43.
24. Nagata N, Kobayashi M, Kojima H, et al: Phase I study of pacltaxel and cisplatin for patients with advanced or recurrent gastric cancer. Hepatogastroenterology 2005; 52:1905-1910.
25. Therasse P, Arbuck SG, Eisenhauer EA et al: New Guidelines to evaluate the response to treatment in solid tumor. J Natl Cancer Inst 2000; 92:205-216.
26. Ohtsu A, Shimada Y, Shirao K, et al: Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer. The Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol 2003; 21(1):54-59.
27. Chang HM, Kim TW, Ryu BY, et al: Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-flurouracil and platinum. Jpn J Clin Oncol 2005; 35(5):251-255.
28. Eric KR, Ross CD: Paclitaxel (Taxol). N Engl J Med 1991; 332:1004-1014.